A Phase 3 interventional study of F2695 and placebo in Ischemic Stroke, sponsored by Pierre Fabre Medicament. Completed at 87 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2015-04-01.
Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Ischemic Stroke with a site in Russian Federation — 6 open to participants now, 6 under way, none of them phase 3. Ischemic Stroke · Russian Federation.
Among the 28 studies in Ischemic Stroke with a site in Russian Federation, this one is the 5th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2012, is one of 8 in phase 3, and was the 3rd registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →6 of the 28 studies in Ischemic Stroke with a site in Russian Federation are open now. Recruiting first, the newest first:
Neurotechnika · Sites in Russian Federation
Ages 18–80
Skolkovo Institute of Science and Technology · Sites in Russian Federation
Ages 35–70 · Healthy volunteers
POLYSAN Scientific & Technological Pharmaceutical Company · Sites in Russian Federation
Ages 18+
POLYSAN Scientific & Technological Pharmaceutical Company · Sites in Russian Federation
Ages 18+
Mikhail Zykov · Sites in Russian Federation
Ages 18+
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 532 is above the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 120 across the 19 interventional studies, 500 across the 9 observational. Of the 17 that completed or were terminated, 8 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pierre Fabre Medicament, one of the names counted as Pierre Fabre. Under that name alone:
Pierre Fabre Medicament is the lead sponsor of 73 studies on the registry; 6 are open to participants now.
Pierre Fabre has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 28 studies in Ischemic Stroke with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy of a new serotonin-norepinephrine reuptake inhibitor (SNRI) nin functional recovery after ischemic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: F2695
Drug: placebo
75 mg OD in 2 capsules
2 capsules
Percentage of patients with a Modified Rankin Scale (mRS) less than or equal to 1 at Week 12
Time frame: week 12
Percentage of patients with NIHSS score less than or equal to 5 at Week 12
Time frame: week 12
Percentage of patients with at least one moderate to severe depressive
Time frame: Baseline to week 12
Change from baseline to Week 12 of the mean NIHSS total and motor scores
Time frame: baseline to week 12
Safety and tolerability assessed by the investigator including SAEs, AEs, vital signs, ECG,physical examination and laboratory tests
Time frame: baseline to week 12
Percentage of patients with a mRS score less than or equal to 2 at Week 12
Time frame: baseline to week 12
The record gives a start of Jul 2012, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levomilnacipran